Monitoring drug therapy

British Journal of Clinical Pharmacology

Volumn 73, Issue 6, 2012, Pages 917-923

  Buclin, Thierry ^a   Gotta, Verena ^a   Fuchs, Aline ^a   Widmer, Nicolas ^a   Aronson, Jeffrey ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; CYCLOSPORIN; DIGOXIN; LITHIUM; PHENYTOIN; THEOPHYLLINE;

BONE DENSITY; CHRONIC DISEASE; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MANUFACTURE; DRUG RESPONSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GOVERNMENT REGULATION; NOTE; PATIENT MONITORING; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED KINGDOM;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG MONITORING; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY;

EID: 84860690808     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04237.x     Document Type: Note

References (33)

1. Glasziou P, Aronson JK. An introduction to monitoring therapeutic interventions in clinical practice. In: Evidence-Based Medical Monitoring: From Principles to Practice, eds Glasziou P, Irwig L, Aronson JK. Oxford: Wiley-Blackwell Ltd, 2008; 3-14.
2. Widmark EMP. Die theoreischen Grundlagen und praktische Verwendbarkeit der gerichtlich-medizinischen Alkoholbestimmung. Berlin: Urban & Schwarzenberg, 1932.
3. Van der Helm HJ, Andriesse D. The determination of lithium in serum during therapy with lithium salts. Clin Chim Acta 1961; 6: 747-8.
4. Löwenstein JM. A method for measuring plasma levels of digitalis glycosides. Circulation 1965; 31: 228-33.
5. Roe JH, Irish OJ. Sugar threshold in one hundred cases of diabetes. JAMA 1925; 84: 1406-7.
6. Quick AJ, Hussey CV, Kaser M. The action of dicumarol in the human being on plasma prothrombin time and total prothrombin time. Am Heart J 1952; 44: 119-23.
7. Aronson JK, Hardman M, Reynolds DJM. ABC of Monitoring Drug Therapy. London: BMJ Publishing Group, 1993.
8. Burton M, Evans WE, Schentag JJ, Shaw L. Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring, 4th edn. Baltimore, MD: Williams & Wilkins, 2006.
9. Ensom MH, Davis GA, Cropp CD, Ensom RJ. Clinical pharmacokinetics in the 21st century; does the evidence support definitive outcomes? Clin Pharmacokinet 1998; 34: 265-79.
10. Pirmohamed M, Ferner RE. Monitoring drug treatment. BMJ 2003; 327: 1179-81.
11. Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol 2001; 52 (Suppl. 1): 5S-10S.
12. Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn 2006; 33: 227-79.
13. Lathia CD, Amakye D, Dai W, Girman C, Madani S, Mayne J, MacCarthy P, Pertel P, Seman L, Stoch A, Tarantino P, Webster C, Williams S, Wagner JA. The value, qualification, and regulatory use of surrogate end points in drug development. Clin Pharmacol Ther 2009; 86: 32-43.
14. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112: 281-9.
15. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents is related to changes in bone density. J Clin Endocrinol Metab 2000; 85: 231-6.
16. Bell KJ, Hayen A, Macaskill P, Irwig L, Craig JC, Ensrud K, Bauer DC. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ 2009; 338: b2266.
17. Aronson JK, Ferner RE. Joining the DoTS. New approach to classifying adverse drug reactions. BMJ 2003; 327: 1222-5.
18. Glasziou P, Irwig L, Mant D. Monitoring in chronic disease: a rational approach. BMJ 2005; 330: 644-8.
19. Ellington C, Grgurinovich N, Miners JO, Mangoni AA. Quality of requests for serum digoxin concentrations: experience from an Australian regional health service. Br J Clin Pharmacol 2007; 63: 623-7.
20. Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A, LIPID Study Investigators. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med 2008; 148: 656-61.
21. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.
22. Glasziou PP, Irwig L, Aronson J. Evidence-Based Medical Monitoring: Principles and Practice. Oxford: BMJ Books, Blackwell Publishing, 2008.
23. Sheiner LB, Beal S, Rosenberg B, Marathe VV. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979; 26: 294-305.
24. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6: 429-53.
25. Buclin T, Widmer N, Biollaz J, Decosterd LA. Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. Lancet Oncol 2011; 12: 9-11.
26. Woodcock J. Assessing the clinical utility of diagnostics used in drug therapy. Clin Pharmacol Ther 2010; 88: 765-73.
27. Scherf U, Becker R, Chan M, Hojvat S. Approval of novel biomarkers: FDA's perspective and major requests. Scand J Clin Lab Invest Suppl 2010; 242: 96-102.
28. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010; 363: 301-4.
29. Laurence CO, Gialamas A, Bubner T, Yelland L, Willson K, Ryan P, Beilby J, Point of Care Testing in General Practice Trial Management Group. Patient satisfaction with point-of-care testing in general practice. Br J Gen Pract 2010; 60: e98-104.
30. Gialamas A, St John A, Laurence CO, Bubner K, PoC Management Committee. Point-of-care testing for patients with diabetes, hyperlipidaemia or coagulation disorders in the general practice setting: a systematic review. Fam Pract 2010; 27: 17-24.
31. Garcia-Alamino JM, Ward AM, Alonso-Coello P, Perera R, Bankhead C, Fitzmaurice D, Heneghan CJ. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev 2010; (4): CD003839.
32. Holford NH. Target concentration intervention: beyond Y2K. Br J Clin Pharmacol 2001; 52 (Suppl. 1): 55S-9S.
33. Hovorka R, Kumareswaran K, Harris J, Allen JM, Elleri D, Xing D, Kollman C, Nodale M, Murphy HR, Dunger DB, Amiel SA, Heller SR, Wilinska ME, Evans ML. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011; 342: d1855.